Compare AbbVie Inc (ABBV) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Lowe`s Companies Inc — how do they compare? AbbVie Inc trades at $253.2 (market cap $449.91B), while Lowe`s Companies Inc trades at $215 (market cap $123.86B). The key difference: AbbVie Inc is far larger — about 3.6× Lowe`s Companies Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | LOW | |
|---|---|---|
Market Cap | $449.91B | $123.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $287.39 |
52-Week Low | $184.85 | $206.62 |
Enterprise Value | $513.38B | $165.61B |
Dividend Yield | 2.72% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Lowe's (LOW) trades at $220.9, down 2.9% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 60.79% buy rating from analysts support optimism, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. The stock's P/E of 18.92 and net income margin of 7.51% reflect solid profitability, while dividend increases counter earlier Wall Street skepticism about payout sustainability.
The outlook is positive with a $260.88 consensus price target, but risks include high debt levels, competitive pressure from Home Depot, and macroeconomic sensitivity. Earnings growth and professional market expansion are key catalysts, though inflation and housing market softness pose headwinds for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
